Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Investments (2020 - 2025)

Bioventus' Long-Term Investments history spans 6 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 21.19% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 21.19%, while the annual FY2025 figure was $2.3 million, 21.19% up from the prior year.
  • Long-Term Investments reached $2.3 million in Q4 2025 per BVS's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $78.5 million in Q3 2022 to a low of $1.7 million in Q2 2025.
  • Average Long-Term Investments over 5 years is $12.3 million, with a median of $3.2 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: surged 302.84% in 2022, then plummeted 91.67% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $16.8 million in 2021, then tumbled by 84.37% to $2.6 million in 2022, then grew by 19.84% to $3.1 million in 2023, then plummeted by 39.76% to $1.9 million in 2024, then increased by 21.19% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Long-Term Investments are $2.3 million (Q4 2025), $2.3 million (Q3 2025), and $1.7 million (Q2 2025).